If you have Graves' disease, toxic nodules, or thyroiditis, your endocrinologist and primary care provider should review your GLP-1 plan collaboratively
Nutritional considerations for off-label use Some individuals use microdosing, spaced out dosing, or lower compounded dosing of GLP-1s
For non-diabetics taking GLP agonists for other reasons most likely reducing body weight the results of this study may not be applicable as the interaction of diabetes-related inflammation, and such may be the reason for such wide-ranging GLP agonist effects. The study authors conclude that their results provide insights into the benefits and risks of GLP-1R and may be useful for informing clinical care and guiding research agendas
Several studies have found that eating carbohydrates later in a meal and consuming protein-rich foods first may increase GLP-1 secretion
Retatrutide is a medicine for weight loss currently being developed by Eli Lilly
In the 1970s, Harvard University researcher Joel Habener, with support from the National Institutes of Health, set out to study the hormone glucagon and its role in blood sugar regulation
